🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Tissue Expansion

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites📍 Los Angeles📍 Denver📍 Nashville RasCal Therapeutics, Inc. · Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors NCT06926283Phase 14 sites📍 Changsha📍 Hangzhou📍 Beijing Hangzhou DAC Biotechnology Co., Ltd. · Tests: DXC008 TT-702 in Patients With Advanced Solid Tumours. NCT05272709Phase 1, Phase 23 sites📍 London📍 Manchester📍 Southampton Cancer Research UK · Tests: TT-702, Anti-PD-1 and PD-L1 agent A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites📍 Duarte📍 Grand Rapids📍 Long Island City Pfizer · Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer NCT06508216Phase 1, Phase 21 site📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: Dato-DXd, Durvalumab A Study of PHST001 in Advanced Solid Tumors NCT06840886Phase 120 sites📍 Beverly Hills📍 Los Angeles📍 Palo Alto Pheast Therapeutics · Tests: PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma NCT06797999Phase 1, Phase 29 sites📍 Aurora📍 Miami📍 New York Adcendo ApS · Tests: Antibody-drug conjugate (ADC) A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963Phase 114 sites📍 Newport Beach📍 Edgewood📍 Boston NextCure, Inc. · Tests: LNCB74 A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases NCT07268053EARLY Phase 11 site📍 Phoenix Nader Sanai · Tests: Risvutatug rezetecan IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer NCT04947189Phase 1, Phase 21 site📍 Darlinghurst St Vincent's Hospital, Sydney · Tests: Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863Phase 121 sites📍 Scottsdale📍 Tucson📍 Los Angeles Clasp Therapeutics, Inc. · Tests: CLSP-1025 Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors NCT05283330Phase 18 sites📍 Chicago📍 Iowa City📍 Lexington Orano Med Theranostics, SAS · Tests: ²¹²Pb-DOTAM-GRPR1 A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites📍 Santa Monica📍 New Have📍 Camperdown Kivu Bioscience Inc. · Tests: KIVU-107 A Study of DXC014 in Patients With Advanced Solid Tumors. NCT07177937Phase 15 sites📍 Beijing📍 Changsha📍 Nanchang Hangzhou DAC Biotechnology Co., Ltd. · Tests: DXC014 Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194Phase 1, Phase 26 sites📍 Denver📍 Miami📍 Boston ModeX Therapeutics, An OPKO Health Company · Tests: MDX2001 HER-2 B Cell Peptide Vaccine NCT06414733Phase 11 site📍 Indianpolis Pravin T.P Kaumaya · Tests: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51 Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors NCT07424547Phase 15 sites📍 Plantation📍 Plantation📍 Austin Conjupro Biotherapeutics, Inc. · Tests: SYS6043 Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors NCT06132503Phase 11 site📍 West Valley City Lantern Pharma Inc. · Tests: LP-284 Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation NCT04890613Phase 18 sites📍 Santa Monica📍 Tampa📍 Boston Senhwa Biosciences, Inc. · Tests: CX-5461 Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma NCT07551336Phase 11 site📍 Shenzhen Beijing Biotech · Tests: Dual-target CAR-NK cells, Cyclophosphamide, Intracranial catheter/reservoir for locoregional delivery, Fludarabine Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma NCT06410248Phase 11 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Resection, Temozolomide A Study of BI 3810944 in Patients With Advanced Cancer NCT07224425Phase 17 sites📍 Louisville📍 Nashville📍 Houston Boehringer Ingelheim · Tests: BI 3810944 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Study of XB010 in Subjects With Solid Tumors NCT06545331Phase 120 sites📍 Irvine📍 Los Angeles📍 Washington D.C. Exelixis · Tests: XB010, Pembrolizumab Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer NCT05491083Phase 1, Phase 21 site📍 Singapore National University Hospital, Singapore · Tests: Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy People for the Expansion of T Cells for Adoptive Cell Therapy NCT02821806n/a1 site📍 Bethesda National Cancer Institute (NCI) A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NCT06805825Phase 15 sites📍 Ann Arbor📍 Cleveland📍 Portland Novelty Nobility, Inc. · Tests: NN3201
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy